微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志 ›› 2013, Vol. 5 ›› Issue (2): 151-154.doi: 10.3969/j.issn.1674-5671.2013.02.17

• 临床研究 • 上一篇    下一篇

美罗华联合CHOP方案治疗弥漫性大B细胞淋巴瘤的疗效观察

  

  1. 广西医科大学附属肿瘤医院化疗二科
  • 出版日期:2013-06-25 发布日期:2013-06-27
  • 通讯作者: 宋向群 E-mail:xiangquns@163.com

Effects of a combined Rituximab and CHOP regimen in patients with diffuse large B-cell lymphoma

  • Online:2013-06-25 Published:2013-06-27

PDF (PC)

869

赞

被引次数

22

摘要： 目的 观察美罗华联合CHOP方案治疗弥漫性大B细胞淋巴瘤的疗效及不良反应。方法 48例CD20阳性的弥漫性大B细胞淋巴瘤患者，随机分为观察组和对照组，每组24例。观察组采用美罗华联合CHOP方案化疗，对照组单用CHOP方案化疗。全部患者完成6个周期化疗后评价疗效。结果 观察组和对照组的总有效率分别为91.7%（22/24）和66.7%（16/24），1年总生存率（OS）分别为95.8%和74.7%，3年OS分别为83.3%和50.0%，1年无进展生存率（PFS）分别为82.6%和57.3%，3年PFS分别为62.8%和37.2%，以上两组比较差异均有统计学意义（P<0.05）。两组患者的不良反应主要为胃肠道反应、骨髓抑制和输液相关不良反应。除畏寒、发热外，其余不良反应的发生率差异均无统计学意义（P＞0.05）。结论 美罗华联合CHOP方案治疗弥漫性大B细胞淋巴瘤疗效较好，未增加化疗毒性，安全性好，值得临床推广应用。

关键词: 淋巴肿瘤, 美罗华, CHOP, 疗效

Abstract: Objective To evaluate the efficacy and toxicity of rituximab plus CHOP in patients with diffuse large B-cell lymphoma. Methods A total of 48 patients with histopathologically confirmed CD20-positive diffuse large B-cell lymphoma were randomly as-signed into two groups：24 received CHOP plus rituximab（R-CHOP group），and 24 received CHOP alone（CHOP group）.All patients received six chemotherapy cycles，and the therapeutic effect was assessed. Results The overall response rate was 91.7%（22/24） in the R-CHOP group and 66.7%（16/24） in the CHOP group（P<0.05）.The 1-and 3-year survival rates were 95.8% and 83.3% in the R-CHOP group，and 74.7% and 50.0% in the CHOP group.The 1-and 3-year progression-free rates were significantly higher in the R-CHOP group（82.6% and 62.8%） than in the CHOP group（57.3% and 37.2%， P<0.05）.The major side effects in the two groups were myelosuppression，gastrointestinal toxicity and infusion-related adverse reactions.The two groups did not differ significantly in adverse reactions， except chills and fever. Conclusion Combination chemotherapy including Rituximab and CHOP（R-CHOP） is effective and well-tolerated by patients， suggesting it is a good treatment for diffuse large B-cell lymphoma.

Key words: Lymphoma, Rituximab, CHOP regiment, Therapeutic effect